Biotech Assistant
Share useful research with your peers
in · Share on LinkedIn ↗
BIOTECH ASSISTANT / FIELD NOTES

Haoyuan Chemexpress reports nine-month revenue growth of 28.52%

Regulatory / securities filing · 皓元医药 / 巨潮资讯 CNinfo

Source published: · Event / reporting date: 2026-09-30

Site published: 2026-11-03 · Updated: 2026-11-03

Explore this article with AI

This source is linked automatically. Choose a question to get started.

Ask AI ↗
Findings and limitationsIndustry implicationsRelated developments

What changed

Haoyuan Chemexpress reported consolidated revenue of RMB2.646 billion, up 28.52%, and attributable net income of RMB308.8 million for the nine months ended September 30, 2026. Attributable net income rose 30.49%. Consolidated revenue combines multiple businesses rather than isolating CDMO service revenue. The quarterly filing is unaudited and covers the year-to-date period.

Why it may matter

Growth at the integrated platform offers an industry reference point, but comparisons still require separating research products from CDMO services.

The interpretation above is analysis, not a conclusion attributed to the original source.

Read the original source ↗

Prepared through Biotech Assistant’s automated research workflow. Editorial standards and corrections

China-listed CRO/CDMO

Follow the evidence

Companies mentionedHaoyuan ChemExpress ↗
Explore field companies →Explore literature →

Related updates

Bio-S Pharmaceutical

Bio-S and XtalPi unveil joint drug-discovery platform in Shanghai

Bio-S Pharmaceutical reported that its joint platform with XtalPi, Hangzhou Baijingyao Biotechnology, was unveiled in Shanghai on November 5. The partners described plans to combine AI-driven discovery with experimental validation, drug development, and clinical translation. The November 6 announcement presents an operating strategy and platform milestone, rather than a quantified licensing transaction or validated clinical outcome.

Companies mentionedXtalPi ↗
China-listed CRO/CDMOAsk AI ↗
Fresenius

Fresenius gains development options on up to 37 WuXi Biologics biosimilar candidates

Fresenius signed an exclusive development agreement with WuXi Biologics providing access to up to 37 biosimilar candidates over the next decade. Initial work is expected to focus on polatuzumab vedotin and teprotumumab biosimilars. Fresenius retains selection flexibility and commercialization economics; the candidate count is an option-based opportunity, not 37 approved products.

Companies mentionedWuXi Biologics ↗
China-listed CRO/CDMOAsk AI ↗
百奥赛图 / 巨潮资讯 CNinfo

Biocytogen reports nine-month revenue growth of 49.09%

Biocytogen reported consolidated revenue of RMB1.403 billion, up 49.09%, and attributable net income of RMB312.4 million for the nine months ended September 30, 2026. Attributable net income increased 173.77%. The group combines animal models, research services, and antibody licensing activities. The quarterly filing is unaudited and covers the year-to-date period.

Companies mentionedBiocytogen ↗
China-listed CRO/CDMOAsk AI ↗

Continue your research

All company profiles, filters, and comparisons are open. Sign in for private saves and member discussions.

Open full company map ↗
AI assistant ↗